Novel t-cell receptor
AssigneeUniversity College Cardiff Consultants Limited
InventorsAndrew SEWELL, Garry DOLTON
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.
Claims19
A vector encoding a tumour specific T-cell receptor (TCR) wherein the TCR comprises (i) an a chain having three a chain complementarity-determining regions (CDRs) comprising the sequences:
- TSESDYY (SEQ ID NO:3) as CDR1α, ATEN (SEQ ID NO:4) as CDR2α and CAYRSAVNARLMF (SEQ ID NO:
- 1) as CDR3α and (ii) a 13 chain having three 13 chain CDRs comprising the sequences:
- MGHDK (SEQ ID NO:5) as CDR113, SYGVNS (SEQ ID NO:6) as CDR2β and CASSEARGLAEFTDTQYF (SEQ ID No:
- 2) as CDR3β.
A T-cell comprising a vector encoding a tumour specific T-cell receptor (TCR) wherein the TCR comprises (i) an a chain having three a chain complementarity-determining regions (CDRs) comprising the sequences:
- TSESDYY (SEQ ID NO:3) as CDR1α, ATEN (SEQ ID NO:4) as CDR2α and CAYRSAVNARLMF (SEQ ID NO:
- 1) as CDR3α and (ii) a β chain having three β chain CDRs comprising the sequences:
- MGHDK (SEQ ID NO:5) as CDR1β, SYGVNS (SEQ ID NO:6) as CDR2β and CDR CASSEARGLAEFTDTQYF (SEQ ID No:
- 2) as CDR3β and wherein the T-cell expresses said TCR.
Dependencies are inferred from the claim text.